ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1314

Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis

Haluk Cinaklı1, Elif Ediboglu1, Eda Otman Akat2, Dilek Solmaz3, Gulay Alp1, Esra Erpek1, Sercan Gücenmez4, Mustafa Ozmen4 and Servet Akar3, 1Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 2katip çelebi, izmir, Turkey, 3Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, 4katip çelebi university, izmir, Turkey

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Anti-TNF Drugs, Back pain, Eye Disorders, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute anterior uveitis (AAU) is the most frequent extra musculo-skeletal manifestation of axSpA which may lead to severe functional impairment. Moreover, an AAU attack can be the presenting symptom that may lead to diagnosis of axSpA. However, there is limited data regarding the factors predicting the development of AAU attacks in patients with axSpA.

Purpose: To examine the factors associated with the AAU attacks in patients with axSpA in a longitudinal axSpA cohort.

Methods: In total 469 axSpA patients (272 [58%] male; 297 [63%] with AS and 172 [36%] with non-radiographic (nr)-axSpA) who have followed up to three years were included in this observational study. Baseline disease characteristics and follow-up data including the development of AAU attacks, concurrent disease activity, serum CRP levels, usage of conventional synthetic and biological disease modifying anti-rheumatic drugs (cs-DMARD, bDMARD) were collected on 3, 6, 12, 24 and 36th months. The longitudinal relationship between AAU attacks (dependent) and potential predictive factors (independent) tested by using generalized estimating equations (GEE) which is a technique for longitudinal data analysis allowing the use of all available data even deviated from normality.

Results: Overall, 99 (%21) of 469 patients had experienced at least one AAU attack (77 [78%] on history and 31 of them also in follow up, 11 patients [11%] presented with AAU in their first visits and 11 have developed their first AAU attacks on follow up) (Table 1). In total 89 AAU attacks were observed during follow up (35 attacks on presentation, 10 attacks at 3nd month, 4 attacks at 6th month, 12 attacks at 12ndmonth, 16 attacks at 24th month and 12 attacks at 36th months of follow up). At baseline patients with the AAU history were older (p=0.001), had more peripheral arthritis (p< 0.001), higher BASMI score (p=0.007), and higher serum CRP levels (p=0.016). Those patients with a positive AAU history have been also using cs- and bDMARD more commonly. Univariate longitudinal analysis revealed that the development of AAU attacks was significantly associated with the history of AAU, male gender, the presence of extraspinal involvement, concomitant cs-DMARD usage, BASDAI scores, ASDAS-CRP, and PGA of disease activity. However, multivariate analysis showed that the presence of AAU history and concurrent disease activity assessed by BASDAI were the only independent determinants of the development of AAU attacks in axSpA patients (Table 2).

Conclusion: Our results showed that AAU attacks were significantly higher in axSpA patients who had history of AAU and higher disease activity. Moreover, the presence of AAU might have an impact on treatment in axSpA patients.

Table 1. Baseline characteristics of axSpA patients with and without history of uveitis

Table 2. The factors assosiated with uveitis attacks in patients with axSpA


Disclosures: H. Cinaklı, None; E. Ediboglu, None; E. Otman Akat, None; D. Solmaz, Roche, 6, Farmanova, 6, Pfizer, 6, Lilly, 6; G. Alp, None; E. Erpek, None; S. Gücenmez, None; M. Ozmen, None; S. Akar, AbbVie, 2, 5, 6, Lilly, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Janssen, 2, 5, 6, UCB, 2, 5, 6, Amgen, 2, 5, 6, Gilead, 2, 5, 6, Abdi Ibrahim, 2, 5, 6, Ilko, 2, 5, 6.

To cite this abstract in AMA style:

Cinaklı H, Ediboglu E, Otman Akat E, Solmaz D, Alp G, Erpek E, Gücenmez S, Ozmen M, Akar S. Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/predictive-factors-for-the-development-acute-anterior-uveitis-attacks-in-patients-with-axial-spondyloarthritis-the-results-of-a-longitudinal-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-factors-for-the-development-acute-anterior-uveitis-attacks-in-patients-with-axial-spondyloarthritis-the-results-of-a-longitudinal-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology